Maternal micronutrient consumption periconceptionally and during pregnancy: a prospective cohort study

Michelle Livock1,2,*, Peter J Anderson3,4, Sharon Lewis2,4, Stephen Bowden1, Evelyne Muggli2,4 and Jane Halliday2,4

1Melbourne School of Psychological Sciences, The University of Melbourne, 12th Floor Redmond Barry Building, Parkville, VIC 3010, Australia; 2Public Health Genetics, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia; 3Clinical Sciences, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia; 4Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia

Submitted 18 December 2015: Final revision received 28 June 2016: Accepted 29 June 2016: First published online 3 August 2016

Abstract

Objective: To examine overall micronutrient intake periconceptionally and throughout pregnancy in a population-based cohort of Australian women.

Design: In a prospective cohort study, micronutrient dosages were extracted from self-reported maternal supplement use, recorded pre-conception, and for each trimester of pregnancy. A food frequency scale (DQESv2) captured usual maternal diet for gestational weeks 14–26. The influence of sociodemographic and lifestyle factors associated with supplement use was examined using logistic regression, and changes in micronutrient intakes prior to and throughout pregnancy were assessed using repeated-measures ANOVA analyses.

Setting: Metropolitan hospital sites in Melbourne, Australia.

Subjects: Women with a viable singleton pregnancy were recruited at less than 19 weeks’ gestation (n = 2146).

Results: Compared with non-users, women using supplements during pregnancy were more likely to have planned their pregnancy, be >25 years old, primiparous, Caucasian, non-smokers, have a tertiary education and be consuming a folate-rich diet. Intakes of folate, Fe and Zn were significantly lower in the periconceptional period, compared with other periods (P < 0.001). Intakes below Recommended Daily Intake levels were common both periconceptionally and throughout pregnancy, with 19–46% of women not meeting the Recommended Daily Intake for folate, 68–82% for Fe and 17–36% for Zn. Conversely, 15–19% of women consumed beyond the recommended Upper Limit for folate and 11–24% for Fe.

Conclusions: The study highlights the need for improved public health education on nutritional needs during pregnancy, especially among women with lower educational achievements and income.

Keywords: Dietary supplements, Pregnancy, Folate, Zinc, Iron

Maternal nutritional status during pregnancy is a key factor in the health and development of the offspring, especially in fetal brain development1. Of particular importance during pregnancy are methyl-donor nutrients such as folate and vitamin B12, which are considered to be positively associated with brain growth and cognitive development in the offspring2,3. Folate reduces the risk of neural tube defects in the fetus when consumed in the periconceptional period4, a finding which has led to the fortification of grain with folic acid in many countries5. Zn and Fe have also been implicated in fetal brain development, with in utero deficiencies associated with higher likelihood of preterm birth and poorer attention, learning and memory6–8. Research also suggests that vitamin D is crucial for fetal development. Gestational vitamin D deficiency has been linked to the development of neurological disorders such as autism9 and, more recently, with language impairment in childhood10. An association also exists between vitamin D deficiency during the latter stages of pregnancy and impaired immune functioning and rickets in the offspring11,12.

Given the heightened nutritional requirements during pregnancy1,13, some women are at risk for suboptimal intake when relying on diet alone14,15. To address the perceived gap between diet and recommended nutrient status, consumption of dietary supplements during pregnancy has become increasingly popular, with their prevalence of use ranging from 81 to 97% in developed nations14,16–18. Some studies have characterised the types...
of supplements that women take during their pregnancy\(^{(14,16,19)}\) and others have examined the nutritional intake of pregnant women through diet\(^{(25)}\). Little is known, however, about the total amount of key micronutrients consumed during pregnancy when considering the combined contribution of supplementation and diet. There is also little information on the total nutritional intake of women periconceptually and in very early pregnancy.

Understanding micronutrient consumption patterns throughout pregnancy and during critical periods of fetal development has important implications for public health policies around maternal nutrition in pregnancy. As such, the objective of the present study was to describe total micronutrient consumption through both diet and supplement use in a population-based prospective cohort of pregnant women.

Specifically, we aimed to: (i) describe supplement use in the three months prior to and throughout pregnancy; (ii) describe the socio-economic, demographic and lifestyle factors associated with supplement consumption; and (iii) using dietary and supplemental intake values, compare with the Australian national pregnancy guidelines\(^{(20)}\), the total quantity of key micronutrients consumed both prior to and during pregnancy.

**Method**

**Study population**

The present study is nested within the AQUA (Asking Questions about Alcohol) study\(^{(21)}\). Women were recruited during early pregnancy at one of seven maternity hospitals in Melbourne, Australia, between July 2011 and July 2012. These sites were chosen based on birth numbers, model of booking in for pregnancy and because of strong management support, thus maximising the feasibility of the project. To be included, women were required to have a viable singleton pregnancy, be less than 19 weeks' gestation at the time of recruitment, at least 16 years of age, fluent in English and able to provide informed consent (n 2146). The study protocol provides a detailed description of the population of pregnant women involved in AQUA\(^{(21)}\).

**Data collection**

Prenatal data collection was administered via three self-completed questionnaires covering five time points: Questionnaire 1, completed at recruitment (<19 weeks' gestation), collected information for three months prior to conception (3MP), after conception but before pregnancy awareness (PPA) and after pregnancy awareness until 13 weeks' gestation (T1; n 2146); Questionnaire 2, completed at 26–28 weeks' gestation, covered the second trimester (T2; n 1715, 79-9 %); and Questionnaire 3, at 36 weeks' gestation, covered the third trimester (T3; n 1571, 73-2 %).

Women recorded their use of dietary supplements for each time point. A check list of nine common vitamins and minerals was provided. These included multivitamins, vitamin A, vitamin D, vitamin E, zinc, iron, folic acid, antacids and fish oil, with the option to provide an 'other' response. Women also recorded their use of up to three specific supplements, including the brand and type of supplement, quantity consumed and frequency of use. The nutrient values of these supplements were gathered from product descriptions provided by the manufacturer or supplier, either on the homepage on the Internet or via personal communication.

To calculate the nutrient composition of the dietary supplements, a database was created containing a collated list of reported supplements, with approximately 400 unique entries. Median values were used when detailed nutritional information on a particular supplement was not available (3 % of participants) and when a supplement type was recorded without a corresponding brand (2–14 % of participants).

Information on maternal diet was collected in Questionnaire 2 through a modified FFQ (Dietary Questionnaire for Epidemiological Studies, Version 2 (DQESv2); Cancer Council Victoria, 1996). The DQESv2 is a measure of usual dietary intake and has been validated for use in large-scale epidemiological studies\(^{(22)}\). The questionnaire incorporates cereal foods, sweets, snacks, dairy products, meats, fish, fruit and vegetables. Participants were asked to rate seventy-four specific food types on a 10-point frequency scale ranging from 'never' to multiple times per month, week or day. Global questions regarding quantity and type of hot meals, fruit, vegetables and dairy products typically consumed were also asked, and were used to scale responses. The dietary information collected in Questionnaire 2 has been used as a proxy for participants' usual diet prior to and throughout pregnancy.

Analysis of the FFQ was undertaken by the Cancer Council Victoria. This analysis excluded information on vitamin B12 and vitamin D intake from food\(^{(23)}\). Further, while the Australian Government introduced mandatory fortification of bread flour with folic acid in 2009, it was not possible to modify the calculation of folate intake accordingly\(^{(25)}\).

**Demographic and lifestyle information**

Detailed data on obstetric history, maternal social environment and broader lifestyle factors were also collected at each time point\(^{(21)}\). Factors included in the current analysis were maternal age in years (<25; 25–29; 30–34; 35–40; >40), ethnicity (Caucasian; Asian; Other), pre-pregnancy BMI, parity (0 previous children; 1 previous child; >1 previous children), pregnancy planning (planned; unplanned), educational attainment (secondary schooling; trade/diploma; tertiary education), annual household income in $AU (<30 000; 30 000–69 000; 70 000–100 000; >100 000), and maternal use of tobacco and alcohol (yes; no).
Statistical analyses were conducted using the statistical software package STATA 13.0. Multiple logistic regression was used to assess the independent sociodemographic and lifestyle factors associated with overall supplement use and use of general multivitamins, pregnancy multivitamins, folate-specific supplements and vitamin D supplements. Odds ratios and 95% confidence intervals were calculated.

To assess differences in micronutrient intake over the five time points (from 3MP to T3), one-way repeated-measures ANOVA were conducted. A Greenhouse–Geisser correction was employed where $\varepsilon < 0.75$ and a Huynh–Feldt correction where $\varepsilon > 0.75$. $P < 0.05$ was considered significant in all statistical tests.

Australian Nutrient Reference Values (national dietary guidelines) for pregnancy were used to evaluate nutrient intake among our participants. The current Recommended Daily Intake (RDI) value for folate during pregnancy is 600 µg/d (from combined food and supplemental sources). Typically, women are advised to take a 400 µg folic acid supplement daily in the periconceptional and early pregnancy periods, in addition to consuming folate-rich foods. This recommendation is endorsed by both the US Institute of Medicine and Food Standards Australia New Zealand. The RDI for Fe and Zn intake during pregnancy is 27 mg/d and 11 mg/d, respectively.

Results

Supplement use prior to and during pregnancy

Table 1 shows the distribution of the number and type of supplements consumed at each time point. Sixty-four percent of women were taking a supplement in the periconceptional and pregnancy pre-awareness (3MP and PPA) periods, rising to 88–91% in T1 to T3. Among supplement users, multivitamins (either general or pregnancy-specific) were the most commonly consumed supplements at all stages of pregnancy. Approximately 40% of women from the total sample consumed a folic acid preparation (pregnancy multivitamin, folate-specific supplement and/or folic acid/iodine supplement) periconceptionally, with this figure rising to 62% after pregnancy awareness. There was a steady increase in vitamin D supplementation during pregnancy, and the proportion of women using Fe supplements almost tripled from early pregnancy (T1) to T3.

Demographic, socio-economic and lifestyle factors associated with supplement use

Overall supplement use

Fig. 1(a) and 1(b) show OR and 95% CI for variables associated with supplement use, compared with non-users, in a multivariate model. Results are separated according to gestational timing. See the online supplementary material, Table S1 for full univariate and multivariate analysis information. When adjusted for all other variables, those positively associated with supplement use were pregnancy planning (associated with use pre-conception and T1), consumption of a folate-rich diet in pregnancy (pre-conception, and trimester one prior to pregnancy awareness) and lower pre-pregnancy BMI (T2 and T3).

Significant negative predictors of supplement use, after adjusting for covariates, included Asian ethnicity (negatively associated with use pre-conception and in T1), ‘other’ ethnicity (trimester one prior to pregnancy awareness), maternal age < 25 years (pre-conception, and T1 and T3) or 25–29 years (pre-conception), and having one previous child (pre-conception and T2) or multiple previous children (pre-conception, trimester one, prior to pregnancy awareness, and T2). Additional negative predictors of supplement use included alcohol consumption in pregnancy (negatively associated with use in trimester one, prior to pregnancy awareness) and smoking (pre-conception and trimester one, prior to pregnancy awareness). Finally, annual household income below $AU 100 000 (pre-conception and trimester one, prior to pregnancy awareness) and maternal education to secondary school (pre-conception and T1) or trade/diploma level (pre-conception, and T1 and T3) were also negatively associated with supplement use.

Use of specific supplement types

Variables associated with use of pregnancy-specific multivitamins, general multivitamins, folic acid-specific supplements and vitamin D supplements were also examined in a multivariate model. Tables S2–S5 in the online supplementary material show OR, 95% CI and significance levels for each supplement type across the five time periods.

For pregnancy-specific multivitamins, pregnancy planning was a significant positive predictor of use (associated with use pre-conception and trimester one, prior to pregnancy awareness), as was alcohol consumption (T2 and T3). Significant negative predictors of use included annual household income <$AU 30 000 (T1, T2 and T3), annual household income of $AU 30 000–69 000 (trimester one, post pregnancy awareness), education to secondary school level (pre-conception), Asian (pre-conception and T1, T2 and T3) and ‘other’ ethnicity (trimester one, post pregnancy awareness), and increasing parity (T3).

For general multivitamins, pregnancy planning was negatively associated with use pre-conception and in trimester one, prior to pregnancy awareness. Significant positive predictors of general multivitamin use included education to secondary school level (associated with use pre-conception), Asian ethnicity (T1, T2 and T3), and annual household income of <$AU 30 000 (trimester one, post pregnancy awareness, and T2) and $AU 30 000–69 000 (trimester one, post pregnancy awareness).
Pregnancy planning was a positive predictor for periconceptional use of folic acid supplements (pre-conception and trimester one, prior to pregnancy awareness). Annual household income of $AU 70 000–100 000 was a negative predictor of folic acid supplement awareness. Annual household income of $AU 70 000 per annum.

For vitamin D-specific supplements, Asian (T1 and T3) and ‘other’ ethnicity (pre-conception and trimester one, prior to pregnancy awareness) were significant positive predictors of use, as was increasing BMI (T2 and T3) and maternal age 25–29 years (T2 and T3). Significant negative predictors included alcohol consumption (negatively associated with vitamin D use pre-conception and in T1, T2 and T3) and maternal education to secondary school level (pre-conception and trimester one, post pregnancy awareness).

**Total intake of folate (dietary and supplemental) prior to and during pregnancy**

A one-way repeated-measures ANOVA showed that women’s total combined dietary and supplemental intake of folate differed significantly across time points ($F(2.96, 5065.73) = 50.27, P < 0.001; data not tabulated). In the periconceptional period almost half of women were consuming below the RDI for folate (Fig. 2). During this time the average total folate intake (3MP: 660 (SD 625) µg/d; PPA: 650 (SD 588) µg/d; data not tabulated) was significantly lower compared with intake following pregnancy awareness (T1: 840 (SD 672) µg/d, $P < 0.001$; data not tabulated) and in T2 (760 (SD 604) µg/d, $P < 0.001$; data not tabulated). Women were most likely to overconsume folate in T1, following pregnancy recognition, and average total folate intake was also significantly higher directly after recognition compared with intake in T2 ($P < 0.001$; data not tabulated) and T3 (690 (SD 473) µg/d, $P < 0.001$; data not tabulated).

The proportion of total folate intake from supplement use differed substantially across intake categories, with about 80% of total folate for overconsumers coming from supplements, in contrast to 14–36% for those with total folate consumption below the RDI (Fig. 2).

**Total intake of iron (dietary and supplemental) prior to and during pregnancy**

Total average Fe intake also differed significantly at different stages of the periconceptional and pregnancy periods ($F(2.89, 4952.60) = 89.01, P < 0.001$; data not tabulated). In the 3MP (24.11 (SD 26.93) mg/d; data not tabulated) and PPA periods (23.22 (SD 25.06) mg/d; data not tabulated), average total Fe intake was significantly lower than in the remainder of pregnancy (T1, post awareness: 30.47 (SD 29.66) mg/d, $P < 0.001$; T2: 33.33 (SD 34.42) mg/d, $P < 0.001$; T3: 37.36 (SD 41.33) mg/d, $P < 0.001$; data not tabulated). Relatively few women were meeting the RDI for Fe, with most participants either

---

**Table 1 Distribution of number and type of supplements consumed across five time points in a population-based prospective cohort of women with a viable singleton pregnancy (n 2146), Melbourne, Australia, July 2011–July 2012**

<table>
<thead>
<tr>
<th>Supplement types*</th>
<th>3MP (n 2146)</th>
<th>PPA (n 2146)</th>
<th>T1 (n 2146)</th>
<th>T2 (n 1715)</th>
<th>T3 (n 1571)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>Taking a supplement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nil</td>
<td>64</td>
<td>1379</td>
<td>64</td>
<td>1382</td>
<td>91</td>
</tr>
<tr>
<td>One</td>
<td>36</td>
<td>767</td>
<td>36</td>
<td>764</td>
<td>9</td>
</tr>
<tr>
<td>Two</td>
<td>37</td>
<td>787</td>
<td>37</td>
<td>791</td>
<td>45</td>
</tr>
<tr>
<td>Three or more</td>
<td>18</td>
<td>385</td>
<td>20</td>
<td>428</td>
<td>32</td>
</tr>
<tr>
<td>Fish/cod liver oils</td>
<td>10</td>
<td>207</td>
<td>8</td>
<td>163</td>
<td>14</td>
</tr>
<tr>
<td>General multivitamin</td>
<td>35</td>
<td>22</td>
<td>477</td>
<td>34</td>
<td>22</td>
</tr>
<tr>
<td>Pregnancy/conception multivitamin</td>
<td>55</td>
<td>1</td>
<td>21</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>B vitamin multivitamin</td>
<td>1.5</td>
<td>1</td>
<td>22</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Folate and iodine</td>
<td>2.5</td>
<td>2</td>
<td>30</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Folate</td>
<td>24</td>
<td>15</td>
<td>329</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>Zinc</td>
<td>1</td>
<td>1</td>
<td>18</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Iron</td>
<td>5</td>
<td>5</td>
<td>72</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>&lt;1</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>18.5</td>
<td>12</td>
<td>254</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>Fish/cod liver oils</td>
<td>13</td>
<td>9</td>
<td>186</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>Calcium</td>
<td>1</td>
<td>1</td>
<td>11</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>Vitamin D and calcium</td>
<td>1</td>
<td>1</td>
<td>18</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td>Herbal</td>
<td>5</td>
<td>5</td>
<td>65</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>8</td>
<td>5</td>
<td>108</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Any folic acid preparation†</td>
<td>62</td>
<td>40</td>
<td>853</td>
<td>62</td>
<td>40</td>
</tr>
</tbody>
</table>

3MP, three months prior to conception; PPA, after conception but prior to pregnancy awareness; T1, from awareness to gestational week 13; T2, second trimester; T3, third trimester; SU, proportion of supplement users (%), TS, proportion of total sample (%).

*Categories are not mutually exclusive, as some women are consuming two or more supplement types.

†Includes single or combined use of a pregnancy multivitamin, folic acid-specific supplement and folic acid/iodine supplement.

---
Fig. 1 (Continued on following page)
under- or overconsuming this micronutrient (Fig. 3). There was a significant increase in total average Fe intake for each trimester ($P < 0.01$; data not tabulated), such that almost a quarter of women were consuming beyond the Upper Limit in T2 and T3. Dietary intake of Fe was greatest for those meeting the RDI, with women in this category consuming relatively equal amounts of Fe through diet and supplementation.

**Total intake of zinc (dietary and supplemental) prior to and during pregnancy**

Total average Zn consumption differed significantly at each time point ($F(3, 5138) = 96.84, P < 0.001$; data not tabulated). In the periconceptional period over a third of women did not meet the RDI for Zn (Fig. 4) and total average Zn intake (3MP: 15.20 (sd 9.13) mg/d; PPA: 15.47 (sd 9.23) mg/d; data not tabulated) was significantly
lower than later in T1, following pregnancy awareness (17·89 (sd 7·66) mg/d, P < 0·001; data not tabulated) and in T2 (17·65 (sd 8·18) mg/d, P < 0·001) and T3 (17·13 (sd 8·37) mg/d, P < 0·001; data not tabulated). Total Zn intake was also significantly higher in T1 post awareness and in T2, compared with T3 (P < 0·001; P < 0·01; data not tabulated).

For women meeting or surpassing the RDI, both diet and supplementation contributed to overall intake levels, while for women consuming below the RDI, total intake was predominantly dietary. Overconsumption of Zn was rare at any time point.

**Supplemental intake of vitamin B₁₂ and vitamin D prior to and during pregnancy**

Consumption of vitamin B₁₂ and vitamin D through dietary supplements increased sharply following pregnancy awareness (Table 2). Post awareness, over two-thirds of women were meeting the RDI for vitamin B₁₂, and over
Meeting the RDI for vitamin B₁₂ and for vitamin D, based on supplement use, according to time period, among a population-based prospective cohort of women with a viable singleton pregnancy (n=2146), Melbourne, Australia, July 2011–July 2012 (3MP, three months prior to conception; PPA, after conception but prior to pregnancy awareness; T1, from awareness to gestational week 13; T2, second trimester; T3, third trimester; RDI, Recommended Daily Intake; UL, Upper Limit). Intake levels: RDI = 11 mg/d; UL = 35 mg/d.

80% of women were meeting Adequate Intake levels for vitamin D, through supplementation alone.

**Discussion**

In the current large, prospective pregnancy cohort study, intakes of several key micronutrients important for fetal development were examined across five time points. Following pregnancy awareness, supplement use rose to about 90% and the number of supplements women consumed increased with each trimester. This reflects primarily vitamin D and Fe intake, consistent with the increased need for these micronutrients later in pregnancy (20,26,27).

Low intake of dietary supplements during pregnancy is typically seen in those most at risk for nutritional deficiencies (based on sociodemographic characteristics), and this was found in the present study with low household income being a negative predictor. Positive predictors of supplement use were pregnancy planning, maternal age >25 years, having a first child, Caucasian ethnicity and a tertiary education. In addition, engagement in other positive health behaviours was evident in those using supplements, such as non-smoking, consumption of a folate-rich diet and periconceptional alcohol abstinence.

Women from the lower sociodemographic groups who did consume supplements were more likely to be taking multivitamins, rather than pregnancy-specific multivitamins, the former being cheaper and having lesser quantities of micronutrients. Further, women meeting the RDI for folate, Fe and Zn were typically consuming a higher quantity of these micronutrients through diet, as well as through supplementation, compared with those not meeting the RDI. This indicates that those not meeting dietary requirements have a comparatively nutrient-poor diet which they are less likely to be augmenting with dietary supplements. Public health messages around the importance of nutrition in pregnancy may not be reaching those most at risk and it is plausible that those with a lower income experience barriers to the use of specific-pregnancy preparations.

Women with previous children were also less likely to consume supplements, particularly in the periconceptional period. This lower consumption is unlikely to be due to a lack of awareness around pregnancy nutrition, as multiparous

---

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>3MP</th>
<th>PPA</th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Meeting the RDI for vitamin B₁₂</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>Meeting the RDI for vitamin D</td>
<td>41</td>
<td>890</td>
<td>43</td>
<td>921</td>
<td>68</td>
</tr>
<tr>
<td>Meeting the AI for vitamin D</td>
<td>47</td>
<td>1014</td>
<td>50</td>
<td>1064</td>
<td>81</td>
</tr>
</tbody>
</table>

3MP: three months prior to conception; PPA, after conception but prior to pregnancy awareness; T1, from awareness to gestational week 13; T2, second trimester; T3, third trimester; RDI, Recommended Daily Intake; AI, Adequate Intake (used when RDI cannot be determined). Intake levels: RDI = 2.6 µg/d; vitamin D AI = 5 µg/d.
women have been shown to have greater knowledge than primiparous women\textsuperscript{20}. Instead, it may reflect a reduction in pregnancy planning and health proactiveness for subsequent pregnancies. The higher variability in supplement use throughout pregnancy for multiparous women would seem to support this inference.

Ethnicity impacted supplement choice. Caucasian women were more likely to use pregnancy multivitamins at any time prior to or during pregnancy, while women of non-Caucasian ethnicity were more likely to consume general multivitamins and vitamin D-specific supplements. It is possible that health professionals regularly advise women of darker skin and those in ethnic populations requiring the covering of skin with clothing about their increased need for vitamin D\textsuperscript{(29)}.

Somewhat surprisingly, those women continuing to use pregnancy-specific multivitamins into T2 and T3 (more likely to be Caucasian, have higher annual household income and education, be primiparous, non-smoking and >25 years old) were also more likely to have consumed alcohol in these trimesters. This relationship is consistent with a belief held by some women that low-level consumption of alcohol is associated with low risk, particularly in the context of an otherwise healthy lifestyle\textsuperscript{(30)}. While there is some research evidence to support the idea that good maternal nutrition can ameliorate some of the effects of fetal exposure to alcohol\textsuperscript{(31–33)}, current medical advice recommends abstinence during pregnancy as the safest policy.

Many women failed to meet the RDI for folate, Fe and Zn, particularly in the critical periconceptional period. Compared with previous studies, we report a slight increase in the proportion of women taking folic acid periconceptionally, from approximately 19–35\%\textsuperscript{(14,17,28)} to 40\%. Nevertheless, this indicates that 60\% of women are not consuming a folic acid preparation in this critical time period, despite only 23\% in our sample having an unplanned pregnancy.

Conversely, overconsumption of folate through diet and supplemental sources (beyond 1000 µg/d) was relatively common, particularly late in T1. There is little consensus on whether nutrient intake beyond a level of sufficiency conveys additional advantage during pregnancy, and recent research has found a link between high doses of folic acid during pregnancy (over 5 mg/d) and impaired psychomotor development at 12–23 months of age\textsuperscript{(34)}. High intake of folic acid may also lead to adverse neurological outcomes in the fetus by masking a severe vitamin B\textsubscript{12} deficiency\textsuperscript{(20,35,36)}. Fortunately, when folic acid intake peaked following pregnancy awareness, over two-thirds of women in our sample were meeting the RDI for vitamin B\textsubscript{12} through supplementation.

This pattern of folic acid consumption (lowest periconceptionally and increasing late in T1) does not align with knowledge and policy related to primary prevention of neural tube defects. Therefore, while women may be aware that folic acid plays a role in fetal development, and thus begin consumption of this compound following pregnancy recognition, they may be unaware of the importance of timing.

Total combined consumption of dietary and supplemental Fe was polarised, with the majority of women either over- or underconsuming. There were 20–24\% of women consuming above the RDI, which may have been due to specific prescriptions for an identified Fe deficiency that was not captured in the present study. However, increased Fe stores in women not experiencing Fe deficiency have been associated with gestational diabetes and increased oxidative stress during pregnancy\textsuperscript{(37–39)}.

Of additional concern was the 70\% of women still not reaching the RDI for Fe by T3, despite a progressive rise in average Fe intake from the periconceptional period. As Fe needs are thought to increase in later pregnancy\textsuperscript{(20)}, and animal research has found that Fe deficiency from pre-conception until early in T2 can lead to impairments in fetal neurodevelopment\textsuperscript{(39)}, better monitoring and education around Fe status in women of childbearing age is indicated.

Study strengths

A major strength of the current study was knowledge of women's total nutrient intake, including both diet and supplements. Additionally, by surveying participants at five time points, we were able to measure supplement intake across critical periods of fetal development. To our knowledge, the present study is the first to examine pregnancy micronutrient intake in such detail. A further strength of the research was the large cohort involved and its relatively high retention rate (73\%).

Study limitations

Measurement error inherent in FFQ must be acknowledged. Despite this, recall-based FFQ have been found to be moderately correlated with biomarker methods\textsuperscript{(25)}, particularly for folate, Zn and Fe\textsuperscript{(40)}. The FFQ was administered in T2, given the prevalence of morning sickness and specific food proclivities in early pregnancy. These data were then used as a proxy for women's usual diet across all time points, potentially reducing the accuracy of dietary intake assigned to other periods. However, evidence suggests that dietary patterns tend to remain stable throughout pregnancy\textsuperscript{(41,42)}.

The FFQ we used (DQESv2) does not take into account folic acid fortification of bread flour (introduced in Australia in 2009). However, 27–39\% of Australian households purchase organic bread and breakfast cereals, which are excluded from mandatory fortification requirements\textsuperscript{(45)}. Despite this, it should be noted that a 77\% reduction in low serum folate and an 85\% reduction in low red-blood-cell folate in women of childbearing age have been found one year post the introduction of mandatory fortification\textsuperscript{(44)}. Further, the mean increase in
daily dietary folate following mandatory fortification is estimated to be 159 µg for women of childbearing age (45). Therefore, it is likely that dietary folate is underestimated in the present study.

Finally, while use of self-report dietary supplement information is highly correlated with biomarker methods (46), use of median nutrient values where detailed nutritional information was not available may impact on the overall accuracy of supplement information. As this occurred for only a small minority of cases, it is unlikely to markedly affect results.

**Conclusion**

The present study indicates that over two-thirds of women were consuming supplements periconceptionally and this increased significantly following pregnancy awareness to approximately 90%. When considering the combined contribution of diet and supplementation, the majority of women met the RDI for folate and Zn throughout pregnancy, but failed to do so periconceptionally. In contrast, a significant minority of women consuming high-dose folic acid supplements exceeded the Upper Level for folate, particularly late in T1 and T2. Intake of Fe remained below the RDI for most women both prior to and throughout pregnancy, with those consuming a low dose or no supplemental Fe least likely to meet the recommended target compared with those taking an Fe-specific supplement.

Supplementation plays a large role in overall micronutrient intake during pregnancy and is necessary for many women to reach RDI levels. The present study highlights the need for improvement in public health education on nutritional needs during pregnancy, particularly among women with lower educational attainment and lower household income.

**Acknowledgements**

Acknowledgements: The authors are extremely grateful to all the women and their children for taking part in this study. The authors thank Professor Graham Giles, of the Cancer Epidemiology Centre of The Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies, Version 2. Financial support: This work was supported by the Australian National Health and Medical Research Council (project grant number 1011070, 2011–2014; Senior Research Fellowship to P.J.A., grant number 1081288; Senior Research Fellowship to J.L.H., grant number 1021252) and the Victorian State Government’s Operational Infrastructure Support Program. The study has also received funding from the McCusker Charitable Trust; the Murdoch Childrens Research Institute; the Jack Brockhoff Foundation; and the Foundation for Children.

The funders had no role in the design, analysis or writing of this article. Conflict of interest: The authors report no conflict of interest. Authorship: M.L. performed the analysis and interpretation of results and wrote the manuscript under supervision. P.J.A. and S.L. participated in the planning of the project, assisted with and supervised the statistical analysis and planning and interpretation of results, and critically reviewed the manuscript. S.B. participated in the planning of analyses and critical review of the article. E.M. participated in the planning of the project and assisted with statistical analysis, interpretation and critical review of the manuscript. J.H. conceived the idea for the research project and assisted with planning, statistical analysis, interpretation and critical review of the manuscript. All authors accept responsibility for the paper as published.

Ethics of human subject participation: This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved by the Eastern Health Research and Ethics Committee (E54/1011) and the Human Research Ethics Committees of Mercy Health (R11/14), Monash Health (11071B), the Royal Women's Hospital (11/20) and the Royal Children’s Hospital (31055A). The latter also approved all follow-up of the children (31055C/D). Written informed consent was obtained from all subjects/patients.

**Supplementary material**

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S1368980016002019

**References**